KR960037833A - 에스케리키아 콜라이에서 항체, 항체 단편 및 항체 단편 융합 분자의 세포질성 발현 - Google Patents

에스케리키아 콜라이에서 항체, 항체 단편 및 항체 단편 융합 분자의 세포질성 발현 Download PDF

Info

Publication number
KR960037833A
KR960037833A KR1019960010691A KR19960010691A KR960037833A KR 960037833 A KR960037833 A KR 960037833A KR 1019960010691 A KR1019960010691 A KR 1019960010691A KR 19960010691 A KR19960010691 A KR 19960010691A KR 960037833 A KR960037833 A KR 960037833A
Authority
KR
South Korea
Prior art keywords
enzyme
antibody
escherichia coli
antibody fragment
antibodies
Prior art date
Application number
KR1019960010691A
Other languages
English (en)
Inventor
오퍼 마르틴
보쓸레트 클라우스
체크 외르그
Original Assignee
슈타인, 라우페
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈타인, 라우페, 베링베르케 아크티엔게젤샤프트 filed Critical 슈타인, 라우페
Publication of KR960037833A publication Critical patent/KR960037833A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명은 에스케리아 콜라이에서의 항체, 항체 단편 및 항체 단편 융합분자의 세포질내 발현에 관한 것이다. 특히, 종양에 대해 지시된 항체 잔기 및 무독성 프로드럭을 절단하여 약물을 제공하는 효소 잔기를 갖는 항체 단편 융함 분자가 각각의 기능적 특성을 유지한채 이 방법으로 유리하게 제조될 수 있다.

Description

에스케리키아 콜라이에서 항체, 항체 단편 및 항체 단편 융합분자의 세포질성 발현
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 에스케리키아. 콜라이(Escherichia coil) β-글루쿠로니다제의 이. 콜라이 균주 RR1으로부터 PCR로의 증폭하고 벡터 KS내로의 클로닝한 것을 도시한다. 제2도는 VH/CH1를 Fab HC프라이머를 정방향 및 역방향으로 사용하여 적용가능한 PCR로 증폭하고, 벡터 KS내로 클로닝한 것을 도시한다. 제3도는 Xbal 및 Ncol로 절단하여 분리한 DNA단편의 벡너내로의 연결을 도시한다. 제5도는 제4도에서 생성된 작제물의 구조(프로모터(trc)-샤인 달가르노 서열(SD)-VK/CK Mab BW 431/26-SD-VH/CH1 Mab 431/26-이. 콜라이 β-글루쿠로니다제 전자 종결 시그날)를 도시한다. 제6도는 TSK-3000 겔 크로마코그래프로 기능적 활성인 Fab-이. 코라이 β-글루쿠로니다제 융합 단백질의 분자량을 측정한 결과를 도시한다.

Claims (6)

  1. 티오레독신 환원효소-결핌 에스케리키아 콜라이 균주를 사용하고 세포질로부터 발현 생성물을 분리하는 단계를 포함하는, 항체, 항체 단편 또는 세포질성 또는 에스케리키아 콜라이 효소를 융합 파트너로서 함유하는 항체 단편-효소 융합 분자의 재조합 발현 방법.
  2. 제1항에 있어서, Fab 단편 또는 항원-결합 영역(sFv)를 발현하는 방법.
  3. 제1항에 있어서, 항체 단편-효소 융합분자의 항체 잔기가 종양 세포에 대해 지시되고 효소잔기가 무독성 프로드럭을 절단가능하여 독성 약물을 제공하는 방법.
  4. 제3항에 있어서, 항체 부위가 사람화되고 효소 부위가 사람 세포질성 효소인 방법.
  5. 에스케리키아 콜라이 β-글루쿠로니다제가 융합 파트너인 항체 단편-효소 융합 단백질.
  6. 제5항에 따른 융합 단백질을 암호하는 유전자.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960010691A 1995-04-11 1996-04-10 에스케리키아 콜라이에서 항체, 항체 단편 및 항체 단편 융합 분자의 세포질성 발현 KR960037833A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19513676A DE19513676A1 (de) 1995-04-11 1995-04-11 Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli
DE19513676.4 1995-04-11

Publications (1)

Publication Number Publication Date
KR960037833A true KR960037833A (ko) 1996-11-19

Family

ID=7759450

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960010691A KR960037833A (ko) 1995-04-11 1996-04-10 에스케리키아 콜라이에서 항체, 항체 단편 및 항체 단편 융합 분자의 세포질성 발현

Country Status (11)

Country Link
US (3) US6008023A (ko)
EP (1) EP0737747B1 (ko)
JP (1) JPH08289794A (ko)
KR (1) KR960037833A (ko)
AT (1) ATE242808T1 (ko)
AU (1) AU713427B2 (ko)
CA (1) CA2173822C (ko)
DE (2) DE19513676A1 (ko)
DK (1) DK0737747T3 (ko)
ES (1) ES2203654T3 (ko)
PT (1) PT737747E (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304254C (en) * 1997-06-11 2012-05-22 Hans Christian Thogersen Trimerising module
WO2000029583A2 (en) * 1998-11-19 2000-05-25 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
EP1642910B1 (en) * 2000-12-05 2012-02-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
CA2454731C (en) * 2001-08-27 2010-11-02 Genentech, Inc. A system for antibody expression and assembly
CN1164541C (zh) * 2001-10-22 2004-09-01 中国石油化工股份有限公司 甲苯选择性歧化和甲苯与碳九及其以上芳烃歧化与烷基转移方法
DE60310385T2 (de) * 2002-03-23 2007-09-20 Research Development Foundation, Carson City Sekretion von proteinen mit mehreren disulfidbindungen in bakterien und verwendungen davon
GB0224082D0 (en) 2002-10-16 2002-11-27 Celltech R&D Ltd Biological products
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
CA2526647A1 (en) * 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies
WO2005027966A2 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
JP4805848B2 (ja) * 2004-02-12 2011-11-02 モルフォテック、インク． 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
GB0425534D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
US7592426B2 (en) 2005-03-10 2009-09-22 Morphotek, Inc. Anti-mesothelin antibodies
EP1879922A2 (en) 2005-04-22 2008-01-23 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
US20090053786A1 (en) * 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
US8388549B2 (en) * 2008-12-29 2013-03-05 St. Jude Medical, Atrial Fibrillation Division, Inc. Anatomical thermal sensing device and method
US11352445B2 (en) 2018-12-31 2022-06-07 Jecho Laboratories Inc. Method for preparing recombinant protein from bacterium and composition containing the same
CN113388631B (zh) * 2020-03-12 2022-08-09 天津大学 一种高产IgG1的重组菌及构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
WO1993006217A1 (en) * 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
WO1993022334A1 (en) * 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie

Also Published As

Publication number Publication date
US6008023A (en) 1999-12-28
ES2203654T3 (es) 2004-04-16
US20050100984A1 (en) 2005-05-12
EP0737747A2 (de) 1996-10-16
EP0737747A3 (de) 2001-03-28
DK0737747T3 (da) 2003-09-22
AU713427B2 (en) 1999-12-02
JPH08289794A (ja) 1996-11-05
AU5053796A (en) 1996-10-24
ATE242808T1 (de) 2003-06-15
DE19513676A1 (de) 1996-10-17
DE59610519D1 (de) 2003-07-17
US7314753B2 (en) 2008-01-01
PT737747E (pt) 2003-10-31
EP0737747B1 (de) 2003-06-11
US6602688B1 (en) 2003-08-05
CA2173822C (en) 2009-06-23
CA2173822A1 (en) 1996-10-12

Similar Documents

Publication Publication Date Title
KR960037833A (ko) 에스케리키아 콜라이에서 항체, 항체 단편 및 항체 단편 융합 분자의 세포질성 발현
Wu et al. Functional production and characterization of a fibrin-specific single-chain antibody fragment from Bacillus subtilis: effects of molecular chaperones and a wall-bound protease on antibody fragment production
JP6313138B2 (ja) アルデヒドタグ、部位特異的タンパク質修飾におけるその使用
Merk et al. Cell-free expression of two single-chain monoclonal antibodies against lysozyme: effect of domain arrangement on the expression
Jiang et al. Expression of Fab fragment of catalytic antibody 6D9 in an Escherichia coli in vitro coupled transcription/translation system
PL415463A1 (pl) Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, fuzje polipeptydowe, komórki gospodarza, sposób wytwarzania fuzji polipeptydowych, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji, wyizolowana cząsteczka kwasu nukleinowego
Dopp et al. Simple, functional, inexpensive cell extract for in vitro prototyping of proteins with disulfide bonds
Jordan et al. Production of recombinant antibody fragments in Bacillus megaterium
Manosroi et al. Secretion of active recombinant human tissue plasminogen activator derivatives in Escherichia coli
KR940008696A (ko) 프로드럭 활성화를 위한 융합 단백질
BRPI0117173A2 (pt) produção constituida de alto nível de antígeno protetor para antraz
Bianchi et al. High‐level expression of full‐length antibodies using trans‐complementing expression vectors
WO2021222762A3 (en) Activatable il2 composition and methods of use
Tokunaga et al. Secretory production of single-chain antibody (scFv) in Brevibacillus choshinensis using novel fusion partner
US7087412B2 (en) Methods for large scale protein production in prokaryotes
KR102504317B1 (ko) 재조합 단백질을 생성시키는 방법
EP1343909A2 (en) Methods for large scale protein production in prokaryotes
Ideno et al. Expression of foreign proteins in Escherichia coli by fusing with an archaeal FK506 binding protein
Schnappinger et al. Extracellular expression of native human anti-lysozyme fragments in Staphylococcus carnosus
EE03074B1 (et) Rekombinantsed eukarüootsed rakud, nende saamiseks vajalikud DNA järjestused, meetod eukarüootsete rakkude konstrueerimiseks ja sekreteeritavate valkude ning biomassi tootmismeetod
Molloy et al. Production of soluble single-chain T-cell receptor fragments in Escherichia coli trxB mutants
Lee et al. The soluble expression of the human renin binding protein using fusion partners: a comparison of ubiquitin, thioredoxin, maltose binding protein and NusA
Sonoda et al. Cytoplasmic production of soluble and functional single-chain Fv-Fc fusion protein in Escherichia coli
Belenkaya et al. The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
EP1239051A3 (en) Human posh-like protein 1

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application